Literature DB >> 10640742

STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma.

C K Lee1, E Smith, R Gimeno, R Gertner, D E Levy.   

Abstract

Lymphocytes derived from mice deficient in STAT1 showed reduced apoptosis and enhanced proliferation in vitro. To understand the involvement of STAT1 in the observed reduction in apoptosis, we examined the levels of caspase and bcl-2 family genes that are involved in cell survival and/or apoptosis. The levels of caspase 1 and 11, two enzymes involved in both cytokine protein processing and induction of apoptosis, were reduced in STAT1-/- cells compared with wild-type. However, the levels of bcl-2 genes were comparable in both mice. STAT1-/- cells also displayed an enhanced proliferation following TCR stimulation. This hyperproliferation could not be ascribed completely to the loss of IFN-gamma-mediated antiproliferation. First, similar phenotypes were also observed in fibroblasts and pre-B cells derived from STAT1-/- mice, which do not produce IFN-gamma. Second, comparisons with cells lacking the gene for IFN-gamma or with cells treated with neutralizing Abs to IFN-gamma only partially mimicked the STAT1-/- phenotype. Interestingly, the kinetics of degradation of p27kip1, a CDK inhibitor, following TCR ligation were faster, and, concomitantly, the up-regulation of CDK2 kinase activity and protein levels were increased in stimulated T cells of STAT1-/- mice relative to those of wild-type mice. Furthermore, STAT1-/- animals were more susceptible to carcinogen-induced thymic tumors, a possible consequence of altered T cell growth and/or survival. These results demonstrate an essential role for STAT1 for lymphocyte survival and proliferation that is only partially dependent on IFN-gamma signaling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640742     DOI: 10.4049/jimmunol.164.3.1286

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  Stat transcription factors in mammary gland development and tumorigenesis.

Authors:  C J Watson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  Stat1-independent regulation of gene expression in response to IFN-gamma.

Authors:  C V Ramana; M P Gil; Y Han; R M Ransohoff; R D Schreiber; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 3.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

4.  The antagonistic effect between STAT1 and Survivin and its clinical significance in gastric cancer.

Authors:  Hao Deng; Hongyan Zhen; Zhengqi Fu; Xuan Huang; Hongyan Zhou; Lijiang Liu
Journal:  Oncol Lett       Date:  2011-09-16       Impact factor: 2.967

5.  Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes.

Authors:  Ramon Gimeno; Chien-Kuo Lee; Christian Schindler; David E Levy
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

6.  Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Authors:  Huihui Ma; Caisheng Lu; Judith Ziegler; Ailing Liu; Antonia Sepulveda; Hideho Okada; Suzanne Lentzsch; Markus Y Mapara
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

7.  Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis.

Authors:  Sudesh Agrawal; Munna L Agarwal; Moitreyee Chatterjee-Kishore; George R Stark; Guy M Chisolm
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

8.  IL-7-dependent STAT1 activation limits homeostatic CD4+ T cell expansion.

Authors:  Cecile Le Saout; Megan A Luckey; Alejandro V Villarino; Mindy Smith; Rebecca B Hasley; Timothy G Myers; Hiromi Imamichi; Jung-Hyun Park; John J O'Shea; H Clifford Lane; Marta Catalfamo
Journal:  JCI Insight       Date:  2017-11-16

9.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

10.  Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection.

Authors:  Martin L Moore; Michael H Chi; Kasia Goleniewska; Joan E Durbin; R Stokes Peebles
Journal:  Viral Immunol       Date:  2008-09       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.